In a double-blind clinical trial, 24 patients with advanced chronic liver disease received 1.2 g of nicotinohydroxamic acid daily and 23 patients received 1.5 g of neomycin. Patients receiving nicotinohydroxamic acid showed significant improvement in blood ammonia levels as compared to patients receiving neomycin. Nicotinohydroxamic acid induced some side effects, such as mild diarrhea, constipation and anorexia, but less than in cases of neomycin.

This content is only available via PDF.
You do not currently have access to this content.